[{"orgOrder":0,"company":"TaiRx","sponsor":"Bora Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Foslinanib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"TaiRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TaiRx \/ TaiRx","highestDevelopmentStatusID":"8","companyTruncated":"TaiRx \/ TaiRx"}]

Find Clinical Drug Pipeline Developments & Deals by TaiRx

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : CVM-1118 (foslinanib) is a new small molecule chemical entity and a potential anti-cancer agent in numerous human cancer cell lines with strong anti-cancer activity, high safety margin, and multiple mechanisms of actions in targeting cancer-specific fact...

                          Brand Name : CVM-1118

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 27, 2022

                          Lead Product(s) : Foslinanib,Sorafenib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : Bora Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank